Flat rate shipping — $9 dry goods · $13 chilled gel 🌿

science safety

Hashimoto's and Sea Moss: A Practitioner-Guided Iodine Protocol

A clinical framework for Hashimoto's patients considering sea moss mapping the iodine-TPO antibody axis, Wolff-Chaikoff escape failure, selenium co-supplementation, and practitioner-supervised titration.

General information, not medical advice. Sea moss contains iodine. Ask your GP before use if you have a thyroid condition, take medication, or are pregnant or breastfeeding. Quality & Testing.

## Introduction: The question Hashimoto's patients actually need answered Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient populations, affecting approximately 5% of the general population with a strong female predominance (Croker et al., 2021). For the growing number of Australians diagnosed with or suspecting autoimmune thyroid disease, sea moss presents a specific dilemma: a marine botanical rich in iodine, the very substrate their inflamed thyroid struggles to process safely. The wellness landscape typically responds to this dilemma in one of two ways. Either sea moss is promoted as a thyroid "healer" language that ignores the dose-dependent autoimmune risk or it is dismissed with a blanket "avoid all iodine" warning that oversimplifies the biochemistry. Neither position serves a Hashimoto's patient making real decisions about their diet. The clinical reality is more nuanced. The relationship between iodine intake and TPO antibody behaviour in autoimmune thyroid disease is dose-dependent, individually variable, and modifiable through co-nutrient strategies. This article maps that relationship, explains why some Hashimoto's patients tolerate moderate iodine while others cannot, and provides a practitioner-supervised micro-dose framework with explicit lab-based stop criteria. **This is not a self-directed protocol. Every step requires practitioner oversight, baseline labs, and defined exit points.** ## The iodine-autoimmunity axis: Why Hashimoto's changes the rules ### How iodine damages an already-inflamed thyroid In a healthy thyroid, iodine is organified by the enzyme thyroid peroxidase (TPO) into thyroid hormones T4 and T3. This process generates reactive oxygen species (ROS) as a normal byproduct. The thyroid neutralises these ROS through endogenous antioxidant systems, including glutathione peroxidase a selenium-dependent enzyme. In Hashimoto's thyroiditis, this system is already compromised. The autoimmune attack targets TPO itself, and the resulting chronic inflammation depletes local antioxidant capacity. When iodine intake increases, TPO activity rises, ROS production accelerates, and the oxidative damage to thyrocytes intensifies amplifying the very autoimmune cascade that defines the disease (Sohn et al., 2024; Teti et al., 2021). > "Increased iodine concentrations induce oxidative stress by increased activation of TPO, and membrane damage by oxidative stress can cause release of intracellular thyroid antigen and lead to the expression of intercellular adhesion molecule 1 (ICAM-1) by thyrocytes." > Teti et al. (2021), *Immunological Research* This mechanism explains why iodine that is entirely safe for someone with a healthy thyroid can provoke a measurable antibody flare in a genetically susceptible individual. ### The dose-response is not linear it is U-shaped Population-level data reveal a U-shaped relationship between iodine status and autoimmune thyroid disease. Both deficiency and excess increase risk, with the lowest prevalence observed in populations with median urinary iodine concentrations between 100 and 200 mcg/L (Teti et al., 2021). Critically, the inflection point for excess-driven autoimmunity appears to begin at median urinary iodine concentrations above approximately 200-300 mcg/L a threshold that can be reached with moderate seaweed consumption on top of a fortified diet. ``` TPO Antibody Risk ^ High | * * | * * * * | * * * * |* * * * Low | * * * * * | * * * * * * * +------|---------|---------|-------> Deficient Adequate Excess (&lt;100) (100-200) (>300) Urinary Iodine Concentration (mcg/L) ``` ## The Wolff-Chaikoff effect: Why Hashimoto's patients cannot "escape" ### The normal protective mechanism When a healthy thyroid encounters a sudden iodine load, it temporarily shuts down hormone synthesis a protective response called the Wolff-Chaikoff effect. Within 24 to 48 hours, the thyroid "escapes" this suppression by downregulating its sodium/iodide symporter (NIS), reducing iodine uptake and resuming normal function (Sohn et al., 2024). ### Escape failure in autoimmune thyroid disease In patients with Hashimoto's thyroiditis, this escape mechanism can fail. The damaged thyroid cannot adequately downregulate NIS expression, and the suppressive effect of excess iodine persists producing prolonged hypothyroidism that may last weeks or, in some cases, become permanent (Sohn et al., 2024). | Feature | Healthy thyroid | Hashimoto's thyroid | | --- | --- | --- | | Wolff-Chaikoff effect onset | Normal transient suppression | Normal transient suppression | | Escape mechanism (24-48 hrs) | Intact NIS downregulation restores synthesis | May fail NIS remains active | | Outcome of iodine load | Transient, self-resolving | Prolonged hypothyroidism possible | | Clinical consequence | Minimal | TSH elevation, symptom worsening, potential medication adjustment | This escape failure is the primary reason a blanket "iodine is safe up to 1,100 mcg/day" statement does not apply to Hashimoto's patients. The NHMRC upper level of 1,100 mcg/day was established for the general population and does not account for the lower inflammatory threshold in autoimmune thyroid disease (NHMRC, 2006; Sohn et al., 2024). ## Progression risk: What the Whickham data tell us The Whickham Survey, a landmark 20-year follow-up study of 2,779 adults in the UK, established the natural history of autoimmune thyroid disease progression (Vanderpump et al., 1995). ### Annual progression rates to overt hypothyroidism - **TPO antibody-positive with mildly elevated TSH:** approximately 4.3% per year - **TPO antibody-positive with normal TSH:** approximately 2.1% per year - **Combined risk factors (female sex, elevated TSH, TPO-positive):** progression risk compounds with each additional factor These figures carry a direct implication for sea moss use: any intervention that raises TPO antibody titres or pushes TSH upward accelerates progression along a trajectory that is already measurably unfavourable. The goal of any iodine-containing supplement in this population must be to avoid worsening these markers and to stop immediately if they deteriorate. > The Whickham Survey remains the foundational longitudinal dataset for understanding the natural history of autoimmune thyroid progression. Its progression rates are widely cited in subclinical hypothyroidism guidelines, including the RACGP and Endocrine Society frameworks. ## The Australian iodine context: Fortification plus sea moss ### Baseline dietary iodine in Australia Since 2009, FSANZ has mandated iodine fortification of bread via iodised salt across Australia. Post-fortification monitoring shows that Australian adults now consume a mean dietary iodine intake of approximately 152 to 177 mcg/day, depending on age and sex a figure that meets or approaches the RDI of 150 mcg/day for most adults (Charlton et al., 2016; FSANZ, 2009). ### Adding sea moss to a fortified diet Iodine content in *Chondrus crispus* is highly variable, ranging from approximately 47 to over 2,000 mcg/g depending on harvest location, season, and batch. At SeaMossVibes, our per-lot ICP-MS testing has recorded concentrations in the range of approximately 187 mcg/g for recent Saint Lucian harvests. The arithmetic is straightforward: | Component | Estimated daily iodine (mcg) | | --- | --- | | Fortified Australian diet (bread, dairy, eggs) | 150-177 | | Sea moss, 2 g dried at 187 mcg/g | ~374 | | **Estimated total daily intake** | **~524-551** | | NHMRC Upper Level (general population) | 1,100 | | Autoimmune inflammatory threshold (individual) | Potentially well below 1,100 | For a Hashimoto's patient, the relevant number is not the UL of 1,100 mcg/day. It is their individual inflammatory threshold the intake level at which TPO antibody titres begin to rise or TSH shifts. This threshold cannot be predicted from population data; it must be measured through serial blood work. For a detailed breakdown of iodine variability across species and lots, see [Iodine and Thyroid Safety](/blogs/learn/science-safety/iodine-thyroid-safety). ## Selenium co-supplementation: Partially offsetting oxidative damage ### The evidence base The Toulis et al. (2010) systematic review and meta-analysis examined selenium supplementation in Hashimoto's thyroiditis across multiple randomised controlled trials. Patients assigned to selenium supplementation for 3 months demonstrated significantly lower TPO antibody titres, with a weighted mean difference of -271.09 (95% CI: -421.98 to -120.19, p < 0.0001) (Toulis et al., 2010). Subsequent meta-analyses have broadly confirmed this finding. Wichman et al. (2017) reported that selenium supplementation significantly reduced thyroid autoantibody levels in patients with chronic autoimmune thyroiditis across a larger pool of trials. ### The mechanism Selenium is the essential cofactor for glutathione peroxidase (GPx), the primary antioxidant enzyme protecting thyrocytes from TPO-generated ROS. In selenomethionine form at 200 mcg/day, supplementation appears to restore some of this antioxidant buffering capacity, partially offsetting the oxidative damage that iodine-driven TPO activity produces. ### Clinical caveats - Selenium does not "cancel out" iodine risk. It modulates one pathway among several. - The 200 mcg/day dose approaches the NHMRC upper level for selenium (400 mcg/day). Exceeding this is not advisable. - Selenomethionine, not sodium selenite, was the form associated with TPO antibody reduction in the Toulis subgroup analysis. - Long-term selenium supplementation above 200 mcg/day has been associated with increased type 2 diabetes risk in some populations. For the full selenium-iodine interaction profile, see [Selenium and Iodine Pairing](/blogs/learn/science-safety/selenium-iodine-pairing). ## The practitioner-supervised micro-dose protocol **This protocol is not a recommendation to use sea moss with Hashimoto's. It is a structured risk-management framework for patients whose practitioner has assessed their individual case and determined that a monitored trial is appropriate.** ### Pre-requisites checklist Before considering sea moss introduction, all of the following must be confirmed: - [ ] Current diagnosis confirmed by a medical practitioner (not self-diagnosed from symptoms alone) - [ ] Baseline blood work within the past 4 weeks: TSH, free T4, free T3, TPO antibodies, thyroglobulin antibodies - [ ] Current medication regimen documented (especially levothyroxine, carbimazole, lithium, amiodarone) - [ ] Practitioner has reviewed baseline labs and explicitly approved a monitored iodine trial - [ ] Sea moss source provides batch-specific ICP-MS COA with iodine quantified in mcg/g - [ ] Sea moss species verified as *Chondrus crispus* (not *Gracilaria* or *Eucheuma*, which have different iodine profiles) - [ ] Patient understands and accepts the stop criteria below - [ ] No current pregnancy, breastfeeding, or active thyroid storm ### Titration schedule | Week | Daily dose (dried *C. crispus*) | Approximate iodine addition (at 187 mcg/g) | Action | | --- | --- | --- | --- | | 1-2 | 0.5 g | ~94 mcg | Monitor symptoms daily; record energy, mood, neck discomfort, heart rate | | 3-4 | 1.0 g | ~187 mcg | Continue symptom log; note any swelling, fatigue change, or palpitations | | 5-6 | 1.0 g (hold dose) | ~187 mcg | **Blood draw at week 6:** TSH, free T4, TPO antibodies | | 7+ | Per practitioner review | Per lot COA | Increase, maintain, or stop based on lab results | ### Absolute stop criteria Discontinue sea moss immediately and consult your practitioner if any of the following occur: - [ ] TPO antibody titre increases by more than 20% from baseline - [ ] TSH rises above your practitioner-defined target range - [ ] TSH falls below 0.4 mIU/L (suggesting iodine-induced thyrotoxicosis) - [ ] New or worsening neck pain, swelling, or visible goitre - [ ] Unexplained tachycardia, tremor, or heat intolerance - [ ] Significant fatigue increase, weight gain, or constipation worsening - [ ] Any symptom your practitioner has pre-identified as an exit trigger ### Self-assessment: Should you even begin this protocol? | Question | If yes | If no | | --- | --- | --- | | Do you have a confirmed Hashimoto's diagnosis from a medical practitioner? | Proceed to next question | Do not begin seek diagnosis first | | Are your TPO antibodies currently below 500 IU/mL and stable? | Proceed to next question | Discuss with endocrinologist before any iodine addition | | Is your TSH currently within your practitioner's target range on stable medication? | Proceed to next question | Stabilise medication first do not add variables | | Has your practitioner explicitly approved a monitored iodine trial? | Proceed to next question | Do not begin without practitioner approval | | Can you access batch-tested *Chondrus crispus* with a published iodine COA? | Proceed to next question | Do not use unverified sea moss iodine dose is unknown | | Can you commit to a 6-week blood retest? | You may be a candidate for this protocol | Do not begin without committed monitoring | ## What this protocol cannot do This framework manages one narrow risk vector: the iodine-TPO antibody axis. It does not address: - **Heavy metal exposure:** Sea moss accumulates arsenic, lead, cadmium, and mercury from coastal waters. Our COA workflow includes ICP-MS for total heavy metals and HPLC-ICP-MS arsenic speciation to separate toxic inorganic arsenic from benign organic arsenosugars. Hashimoto's patients with compromised detoxification pathways should review the COA with their practitioner. - **Drug interactions:** Sea moss can interfere with levothyroxine absorption (timing separation of at least 4 hours is advisable), warfarin (vitamin K content), and potassium-sparing medications. Always disclose sea moss use to your prescriber. - **Carrageenan sensitivity:** While food-grade carrageenan (high molecular weight, >200 kDa) is not converted to toxic poligeenan under normal digestive conditions, individuals with active intestinal inflammation may wish to exercise additional caution. - **Other autoimmune conditions:** Hashimoto's frequently co-occurs with coeliac disease, type 1 diabetes, and other autoimmune conditions. Each adds complexity that this protocol does not cover. ## Mandatory disclosures **TGA disclaimer:** This article is for informational purposes only and does not constitute medical advice. Sea moss products are not evaluated by the Therapeutic Goods Administration (TGA) for the treatment, cure, or prevention of any disease. Nothing in this article should be interpreted as a therapeutic claim. **Iodine upper limit:** The NHMRC tolerable upper intake level for iodine is 1,100 mcg/day for adults in the general population. Individuals with autoimmune thyroid disease may experience adverse effects at intakes well below this level. **Practitioner consultation:** If you have Hashimoto's thyroiditis, Graves' disease, thyroid nodules, cardiovascular disease, are pregnant or breastfeeding, or take anticoagulant medication, consult a qualified medical practitioner before using sea moss in any form. **Heavy metal sourcing:** SeaMossVibes tests each production lot via ICP-MS for total heavy metals and HPLC-ICP-MS for arsenic speciation. Certificates of analysis are available on request. Environmental variability means no two batches are identical. **Species honesty:** The term "sea moss" is commercially applied to multiple species including *Chondrus crispus*, *Gracilaria*, and *Eucheuma cottonii*. These species differ in iodine content, polysaccharide composition, and mineral profiles. Our products use wild-harvested *Chondrus crispus* from Saint Lucia, verified per lot. **Allergy disclosure:** Sea moss is a marine algae product. Individuals with known allergies to seaweed, iodine, or shellfish (due to shared marine environment cross-contamination risk) should exercise caution and consult their practitioner. ## Conclusion Hashimoto's thyroiditis does not automatically disqualify sea moss use, but it fundamentally changes the risk calculus. The iodine in *Chondrus crispus* interacts with an already-compromised TPO system, and the dose that separates benefit from harm is individually determined not derivable from population ULs or marketing claims. The critical safeguards are: baseline labs before any introduction, a verified iodine concentration per lot (not an estimate), a conservative titration that holds dose until blood work confirms safety, and non-negotiable stop criteria tied to objective measurements. Selenium co-supplementation at 200 mcg/day selenomethionine may provide partial oxidative buffering, but it does not eliminate risk. For Hashimoto's patients, the question is not "is sea moss safe?" but rather "is it safe for me, at this dose, at this point in my disease trajectory, as confirmed by these specific lab values?" Only your practitioner and your blood work can answer that question. ## Next step If you are considering sea moss with an autoimmune thyroid condition, start with our [iodine and thyroid safety overview](/blogs/learn/science-safety/iodine-thyroid-safety) to understand the baseline risk framework. Then book a consultation with your GP or endocrinologist to establish baseline TSH, free T4, and TPO antibody levels before making any dietary changes. If your practitioner approves a monitored trial, request a batch-specific COA from your supplier confirming iodine content in mcg/g. Without that number, you cannot calculate your dose. ## References - Charlton, K., Probst, Y., & Kiene, G. (2016). Dietary iodine intake of the Australian population after introduction of a mandatory iodine fortification programme. *Nutrients*, 8(11), 701. https://www.mdpi.com/2072-6643/8/11/701 - Croker, E. E., McGrath, S. A., & Rowe, C. W. (2021). Thyroid disease: Using diagnostic tools effectively. *Australian Journal of General Practice*, 50(1-2). https://www1.racgp.org.au/ajgp/2021/january-february/thyroid-disease-using-diagnostic-tools-effectively - Food Standards Australia New Zealand. (2009). Iodine fortification. https://www.foodstandards.gov.au/consumer/food-fortification/iodine-fortification - Leung, A. M., & Braverman, L. E. (2014). Consequences of excess iodine. *Nature Reviews Endocrinology*, 10(3), 136-142. https://www.nature.com/articles/nrendo.2013.251 - National Health and Medical Research Council. (2006). *Nutrient reference values for Australia and New Zealand including recommended dietary intakes*. Australian Government. https://www.nhmrc.gov.au/about-us/publications/nutrient-reference-values-australia-and-new-zealand-including-recommended-dietary-intakes - Smyth, P. P. A. (2021). Iodine, seaweed, and the thyroid. *European Thyroid Journal*, 10(2), 101-108. https://karger.com/Article/FullText/512971 - Sohn, S. Y., Inoue, K., Rhee, C. M., & Leung, A. M. (2024). Risks of iodine excess. *Endocrine Reviews*, 45(6), 858-879. https://academic.oup.com/edrv/article/45/6/858/7693016 - Teti, C., Panciroli, M., Nazzari, E., et al. (2021). Iodoprophylaxis and thyroid autoimmunity: An update. *Immunological Research*, 69(2), 129-138. https://pmc.ncbi.nlm.nih.gov/articles/PMC8106604/ - Toulis, K. A., Anastasilakis, A. D., Tzellos, T. G., Goulis, D. G., & Kouvelas, D. (2010). Selenium supplementation in the treatment of Hashimoto's thyroiditis: A systematic review and a meta-analysis. *Thyroid*, 20(10), 1163-1173. https://www.liebertpub.com/doi/abs/10.1089/thy.2009.0351 - Vanderpump, M. P., Tunbridge, W. M., French, J. M., et al. (1995). The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. *Clinical Endocrinology*, 43(1), 55-68. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1995.tb01894.x - Wichman, J., Winther, K. H., Bonnema, S. J., & Hegedus, L. (2016). Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: A systematic review and meta-analysis. *Thyroid*, 26(12), 1681-1692. https://www.liebertpub.com/doi/10.1089/thy.2016.0256

Ready to start?

Turn what you learned into a daily ritual

Explore formats and product details, then check the physical label before use.

Explore products →

Listed ingredients · Storage guidance

Read next

  • Listed product details
  • Available report scope
  • Secure checkout
  • Shipping policy available